Christopher Moore

Jan 8, 2025 | biorxiv.org | Ryan Thorpe |Christopher Moore |Stephanie Jones

AbstractThe process by which neocortical neurons and circuits amplify their response to an unexpected change in stimulus, often referred to as deviance detection (DD), has long been thought to be the product of specialized cell types and/or routing between mesoscopic brain areas. Here, we explore a different theory, whereby DD emerges from local network-level interactions within a neocortical column.

May 20, 2024 | biorxiv.org | Carrie Eaton |Christopher Moore |Colby College

AbstractThere is a need to link micro- and macro-coevolution to bridge mechanistic theory and observations of micro-coevolutionary change with observations of macro-coevolutionary patterns. This need is particularly conspicuous in theoretical models of obligate mutualism, where phylogenetic matching is the predicted outcome. However, these theoretical models of obligate mutualism create a mismatch with empirical studies of obligate mutualism, which experience extensive phylogenetic discordance.

Apr 25, 2024 | marejournal.com | Joseph Latina |Christopher Moore

By Joseph Latina, SIOR & Christopher Moore, CCIM, LMT Commercial Realty/CORFAC Int’l. In recent years, the price increases of industrial land in Delaware have been the subject of interest and scrutiny, reflecting broader trends in the state’s economy and real estate market.

Apr 16, 2024 | baytobaynews.com | Christopher Moore

Posted Tuesday, April 16, 2024 10:39 am By promoting fairness and equity in health care, the Ensuring Pathways to Innovative Cures Act safeguards the health and well-being of vulnerable patient populations.” Christopher Moore is the interim executive director of AIDS Delaware. He previously worked for ChristianaCare, most recently as the director of community health education and engagement. As the leader of AIDS Delaware, an organization dedicated to supporting individuals living with HIV, I...

Jan 16, 2024 | biorxiv.org | Christopher Moore |Sareena Rana |Andrea de Castro |Panayiotis Anastasiou

AbstractMutant selective drugs targeting the inactive, GDP-bound form of KRASG12C have been approved for use in lung cancer, but responses are short-lived due to rapid development of resistance. In this study we use a novel covalent tri-complex inhibitor, RMC-4998, that targets RASG12C in its active, GTP-bound form to investigate treatment of KRAS mutant lung cancer in various immune competent mouse models.